Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
6 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparative Proteomics Analysis of Urine Reveals Down-Regulation of Acute Phase Response Signaling and LXR/RXR Activation Pathways in Prostate Cancer(MDPI AG, 2017-12-29); Detecting prostate cancer (PCa) using non-invasive diagnostic markers still remains a challenge. The aim of this study was the identification of urine proteins that are sufficiently sensitive and specific to detect PCa in the early stages. Comparative proteomics profiling of urine from patients with PCa, benign prostate hyperplasia, bladder cancer, and renal cancer, coupled with bioinformatics analysis, were performed. Statistically significant difference in abundance showed 20 and 85 proteins in the 2-D DIGE/MS and label-free LC-MS/MS experiments, respectively. In silico analysis indicated activation, binding, and cell movement of subset of immune cells as the top affected cellular functions in PCa, together with the down-regulation of Acute Phase Response Signaling and Liver X Receptor/ Retinoid X Receptor (LXR/RXR) activation pathways. The most promising biomarkers were 35, altered in PCa when compared to more than one group. Half of these have confirmed localization in normal or PCa tissues. Twenty proteins (CD14, AHSG, ENO1, ANXA1, CLU, COL6A1, C3, FGA, FGG, HPX, PTGDS, S100A9, LMAN2, ITIH4, ACTA2, GRN, HBB, PEBP1, CTSB, SPP1) are oncogenes, tumor suppressors, and multifunctional proteins with highly confirmed involvement in PCa, while 9 (AZU1, IGHG1, RNASE2, PZP, REG1A, AMY1A, AMY2A, ACTG2, COL18A1) have been associated with different cancers, but not with PCa so far, and may represent novel findings. LC-MS/MS data are available via ProteomeXchange with identifier PXD008407. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Assessment of urinary podocalyxin as a biomarker of early diagnosis of hypertensive nephropathy(Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, 2023-10); ; ; Chronically high blood pressure-related kidney injury is known as hypertensive nephropathy (hN). podocyte damage in the pathogenesis of this disease can result in the release of the sialoglycoprotein podocalyxin into the urine, so podocalyxin may be useful in the early diagnosis of hN. the purpose of the study was to examine the relationships between urine podocalyxin level and clinical and biochemical parameters in individuals with hN and to assess the diagnostic utility of urinary podocalyxin as an early marker of hN. participants (114 individuals) were enrolled in this cross-sectional study, including 30 healthy controls and 84 patients with clinically proven chronic hypertension (ch). Biochemical tests were performed on the blood samples. Urinary microalbumin and creatinine levels were measured using immunoturbidimetric and spectrophotometric methods, respectively; urinary podocalyxin level was estimated with eLISa. all ch patients were classified into subgroups according to urine microalbumin/creatinine ratio (UM/CR) and the stage of chronic kidney disease (CKD). The results obtained showed that urinary podocalyxin level was significantly increased in both UM/CR and CKD staging subgroups compared with the healthy control group. A gradual increase in urinary podocalyxin level with cKD stage, especially in IV and V stages, and the higher sensitivity of urinary podocalyxin as compared to UM/CR ratio in early detection of HN was demonstrated. It was concluded that urinary podocalyxin may be an important and highly sensitive marker for early diagnosis of hypertensive nephropathy in patients with chronic hypertension. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The comparative results and informations about analyses of the urinary sediment.(2005); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of performance characteristics of test devices for drugs of abuse in urine produced by different manufacturers(Medical Faculty, Ss. Cyril and Methodius University in Skopje, 2017); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Verification of the qualitative methods with test devices for detection of drugs of abuse in urine(Institute for Public Health of the Republic of North Macedonia, 2018); ; ; ; The verification of the qualitative method with test devices for detection of eight drugs of abuse in urine (amphetamines, methamphetamine, barbiturates, benzoylecgonine, marijuana, 3,4-methylendioxy-methamphetamine, methadone, and opiates) was done using the assessment results from External Quality Assessment Scheme according to verification protocol in our laboratory, which included predefined performance characteristics such as: accuracy, sensitivity and specificity of the method, as well as for method comparison analysis. Our results have shown that qualitative methods for detection of drugs of abuse in urine have fulfilled the predefined criteria in regard to sensitivity, specificity and accuracy for screening purposes. There was a good agreement between the observed results and assessment results. Reliability of the method has fulfilled the predefined criteria with the exception for amphetamine and methamphetamine (weak and none, respectively). As a conclusion we may say that the rapid non-instrumented test devices for detection of drugs of abuse in urine have shown satisfactory verification results and have fulfilled the criteria for intended purposes according to the ISO 15189 Standard.